What is Zacks Research’s Forecast for ARWR FY2026 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Zacks Research lifted their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Wednesday, August 5th. Zacks Research analyst D. Bautz now expects that the biotechnology company will post earnings of ($3.45) per share for the year, up from their prior estimate of ($3.75). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.46) per share. Zacks Research also issued estimates for Arrowhead Pharmaceuticals’ Q4 2026 earnings at ($1.35) EPS.

A number of other equities analysts also recently issued reports on ARWR. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Leerink Partners upped their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th. JPMorgan Chase & Co. increased their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Finally, Sanford C. Bernstein lifted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $97.33.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $88.33 on Monday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a twelve month low of $15.81 and a twelve month high of $95.49. The business has a 50-day moving average price of $80.23 and a 200 day moving average price of $71.64. The firm has a market cap of $12.44 billion, a PE ratio of -39.26 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter last year, the company posted ($1.26) EPS. The company’s revenue was up 171.0% on a year-over-year basis.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently bought and sold shares of the company. Tsfg LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. Optiver Holding B.V. increased its position in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC raised its stake in Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.